ByQuantisnow· · 3m ago·Wall Street’s wire, on your screen.
Stocks in this Quantisnow insightHealth Care
NeuroPace (NPCE) downgraded to Neutral from Overweight by an analyst, with a new $9.00 price target.
Ask Ellis, your AI research assistant, about this story
Historical context for NPCE
Across the 22 sessions after earlier NPCE headlines, the stock closed higher 15 times and lower 7 times, with a median move of 2.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
Keep researching NPCE
- What is Analyst downgrade?A sell-side analyst’s move to a less favorable rating on a stock, such as from Buy to Hold, usually published with a lower price target and rationale.
- Analyst upgrades and downgradesAn analyst upgrade or downgrade is a change in a sell-side analyst’s stock rating. Learn what Buy, Hold and Sell mean, how price targets work and which changes matter.
- NPCE insider tradesEvery buy and sale reported by Neuropace Inc. officers, directors and large holders.
- NPCE earnings historyPast Neuropace Inc. earnings releases, newest first.
- NPCE financial statementsRevenue, profit, cash flow and balance sheet from Neuropace Inc.’s SEC filings.
Quantisnow market dataNASDAQ
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Listed since
- 2021
